# Draig Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/draig-therapeutics

- Industry: Biotechnology
- Headquarters: Cardiff, UK
- Website: www.draigtherapeutics.com/
- Total disclosed funding: $210M
- Latest round: Series B (Jul 2, 2026)
- Investors on record: 12

## About

Based in Cardiff, UK, Draig Therapeutics Limited is a biotechnology company founded in 2024 by Simon Ward and John Atack. The company specializes in developing innovative neuromodulators for neuropsychiatric disorders, with a primary focus on Major Depressive Disorder (MDD). Led by Ivana Magovcevic-Liebisch (CEO) as of July 2026, Draig Therapeutics is advancing novel neuroscience-based therapies to address significant unmet needs in mental health. Draig Therapeutics focuses on the development of next-generation neuromodulators aimed at treating neuropsychiatric disorders, particularly Major Depressive Disorder (MDD). Their lead product, DT-101, is a next-generation AMPA receptor positive allosteric modulator (PAM) designed to restore synaptic balance by modulating crucial neurotransmitters Glutamate and GABA, alleviating MDD symptoms and potentially addressing other neuropsychiatric disorders. Additionally, Draig is advancing a pipeline of selective GABA A receptor modulators for various conditions such as anxiety disorders, bipolar disorder, schizophrenia, and PTSD, targeting a global market for innovative treatment options. The company's anticipated revenue model is centered on strategic partnerships, licensing opportunities, and future commercialization agreements. As its pipeline advances through clinical development, Draig Therapeutics expects to collaborate with healthcare providers, pharmaceutical companies, and research institutions to support clinical trials, product development, and market access for its neuropsychiatric therapies. In July 2026, Draig Therapeutics Limited raised USD 65 million in series B funding led by Deep Track Capital, with participation from Janus Henderson Investors, Marshall Wace, British Business Bank, and Jefferson Life Sciences.

The company is planning to use the July 2026 funding to enhance its capabilities and services.

## Funding rounds

- Series B, Jul 2, 2026, $65M — Marshall Wace, Janus Henderson Investors, Deep Track Capital, British Business Bank, Jefferson Life Sciences
- Series A, Jun 7, 2025, $145M — Schroders Capital, Intermediate Capital Group, Canaan Partners, SR One, SV Health Investors, Access Industries, Sanofi Ventures
- Seed, Sep 1, 2024 — Intermediate Capital Group, SV Health Investors

## Investors

- Intermediate Capital Group — Seed, Series A
- SV Health Investors (https://capitalatlas.ai/funds/sv-health-investors) — Seed, Series A
- Schroders Capital (https://capitalatlas.ai/funds/schroders-capital) — Series A
- Canaan Partners (https://capitalatlas.ai/funds/canaan-partners) — Series A
- SR One (https://capitalatlas.ai/funds/sr-one) — Series A
- Access Industries (https://capitalatlas.ai/funds/access-industries) — Series A
- Sanofi Ventures (https://capitalatlas.ai/funds/sanofi-ventures) — Series A
- Marshall Wace (https://capitalatlas.ai/funds/marshall-wace) — Series B
- Janus Henderson Investors — Series B
- Deep Track Capital (https://capitalatlas.ai/funds/deep-track-capital) — Series B
- British Business Bank (https://capitalatlas.ai/funds/british-business-bank) — Series B
- Jefferson Life Sciences (https://capitalatlas.ai/funds/jefferson-life-sciences) — Series B